Understanding Perimenopause
Perimenopause is the transition before menopause. It commonly lasts four to eight years, can begin in the late thirties, and affects almost every system in the body. Most women are not told about it until they are already inside it.
The global picture
Perimenopause is not a minority experience or a lifestyle complaint. It is a universal biological transition affecting roughly half the population — and it remains one of the most under-taught areas in medicine.
Women postmenopausal by 2025
The World Health Organization estimates that more than a billion women worldwide will be postmenopausal by 2025 — roughly one in eight people alive.
World Health Organization
Reach menopause each year
Tens of millions of women pass through this transition annually. It is one of the largest predictable health events in the human population.
Global demographic estimates
Median symptom duration
The SWAN cohort found vasomotor symptoms persist for a median of 7.4 years — and beyond ten years when they begin in early perimenopause.
SWAN cohort, JAMA Internal Medicine 2015
Receive any treatment
Across international surveys, the large majority of women with bothersome symptoms are never offered effective treatment. This is the gap.
International survey data
The figure of 51 comes from Western cohorts and is repeated as though it were universal. It is not. Average age at natural menopause varies meaningfully across regions, influenced by genetics, parity, nutrition, smoking, altitude and socioeconomic factors.
This matters clinically. A woman experiencing symptoms at 44 may be reassured that she is “too young” on the basis of a statistic that was never derived from a population like hers.
Approximate mean age at natural menopause
Indicative ranges synthesised from regional epidemiological reviews. Individual variation is wide, and these figures should not be used to rule a diagnosis in or out.
What is actually happening
The common mental model — hormones gradually running down like a battery — is wrong, and that error is the source of a great deal of misdiagnosis. In perimenopause the ovaries do not fade smoothly. As the follicle pool depletes, the feedback loop between the brain and the ovaries becomes erratic.
Oestradiol can swing to levels higher than in your twenties and then fall sharply within the same cycle. Follicle-stimulating hormone rises, but unevenly. Ovulation becomes intermittent, so progesterone — which stabilises mood and supports sleep — becomes unreliable well before oestrogen does.
This explains the pattern women describe and clinicians frequently misread: symptoms that appear and vanish, months that feel normal followed by months that feel unmanageable, and blood tests that return “normal” because they sampled one point inside a volatile system.
Why guidelines advise against routine FSH testing
Because FSH fluctuates as much as oestrogen does during the transition, a single measurement has poor diagnostic value. NICE guideline NG23 recommends diagnosing perimenopause and menopause on the basis of symptoms alone in women over 45, without FSH testing. Testing retains a role in women under 40, where premature ovarian insufficiency must be formally assessed, and has limited value between 40 and 45.
Menopause itself is a single retrospective point: twelve consecutive months without a period. Almost everything women experience symptomatically happens before that point — during perimenopause, when hormones are least stable and recognition is least likely.
System by system
Oestrogen receptors are present in the brain, bone, blood vessels, skin, gut and urogenital tract. That is why a hormonal transition produces symptoms that appear unrelated — and why they are so often investigated separately and treated as coincidence.
Oestrogen modulates serotonin, noradrenaline and GABA signalling, and oestrogen receptors are dense in the hippocampus and prefrontal cortex. Fluctuation — not simply decline — destabilises mood regulation and verbal memory. Risk of depressive symptoms roughly doubles during the transition compared with the premenopausal years. For most women, verbal memory performance recovers postmenopause.
Falling oestrogen narrows the hypothalamic thermoneutral zone and upregulates KNDy neurons in the hypothalamus, so small changes in core temperature trigger a full heat-dissipation response. This is the mechanism behind hot flushes and night sweats, and it is the target of the newer non-hormonal neurokinin-3 receptor antagonists.
Bone loss accelerates sharply in the year before the final period and continues for two to three years afterwards, with women losing a substantial proportion of lifetime bone density in that window. This phase is silent — there are no symptoms until fracture. It is also the phase where intervention has the greatest effect.
Oestrogen influences vascular tone, lipid handling and insulin sensitivity. Across the transition, LDL cholesterol and visceral adiposity typically rise while insulin sensitivity falls. Cardiovascular disease is the leading cause of death in women globally, and midlife is when risk trajectory is set — making this the most consequential and least discussed part of the transition.
The vulva, vagina, urethra and bladder are all oestrogen-dependent tissues. Reduced oestrogen causes thinning, reduced elasticity and altered pH — collectively termed genitourinary syndrome of menopause, affecting a large majority of postmenopausal women. Critically, unlike hot flushes this is progressive and does not improve with time. Low-dose vaginal oestrogen is highly effective and minimally absorbed systemically.
Progesterone has sedative activity through allopregnanolone at GABA-A receptors; declining levels alone disrupt sleep architecture, independently of night sweats. Insomnia prevalence rises substantially across the transition. Sleep loss then amplifies brain fog, mood instability, pain sensitivity and appetite dysregulation — which is why sleep is usually the highest-yield thing to treat first.
What the evidence supports
This is a summary of the treatment landscape so you know what exists and what questions to ask. It is not a prescription — every option below depends on individual history, and that assessment belongs with your clinician.
First-line for bothersome vasomotor symptoms
For healthy women under 60, or within ten years of menopause onset, benefits generally outweigh risks. Route matters: transdermal oestradiol avoids first-pass metabolism and is not associated with the increased venous thromboembolism risk seen with oral preparations. Where a uterus is present, endometrial protection is required — micronised progesterone has a more favourable profile than older synthetic progestins.
For genitourinary symptoms, at any age
Highly effective for dryness, discomfort, painful sex and recurrent urinary tract infections. Systemic absorption is minimal, it does not require added progestogen, and it can generally be used long-term. It is markedly underprescribed relative to how common and how treatable these symptoms are.
Where hormones are contraindicated or unwanted
SSRIs and SNRIs, gabapentin, oxybutynin and clonidine all have evidence for vasomotor symptoms. Neurokinin-3 receptor antagonists (fezolinetant, and more recently elinzanetant) act directly on the hypothalamic pathway driving hot flushes and represent the first genuinely new mechanism in decades.
Evidence-based, and not a consolation prize
CBT has good trial evidence for reducing the impact and distress of hot flushes, for insomnia during the transition, and for low mood. It is recommended in guidelines as an active treatment, not merely as support.
The highest-yield lifestyle intervention
Progressive resistance training addresses bone density, muscle mass, insulin sensitivity, mood and sleep simultaneously. Nothing else in the lifestyle category reaches across that many systems at once. Adequate protein supports the muscle-mass response.
Specific indication, narrow evidence base
The 2019 Global Consensus Position Statement supports testosterone for postmenopausal women with hypoactive sexual desire dysfunction where other contributors have been addressed. It is not evidenced for fatigue, mood or cognition, and remains off-label in most countries.
Sources: NICE NG23; The Menopause Society 2022 position statement on hormone therapy; Global Consensus Position Statement on testosterone therapy for women (2019). Availability, licensing and naming of individual medicines vary by country.
Attributing every midlife symptom to hormones causes real harm in the opposite direction. These findings need medical assessment rather than reassurance.
Thyroid disease, iron deficiency, diabetes, obstructive sleep apnoea and depression all overlap substantially with perimenopause and are common in this age group. A good clinician considers them alongside the hormonal picture rather than instead of it.
Symptom Library
Every common symptom with prevalence data, mechanism, what helps, and when to seek review.
ReadTopic Guides
Longer-form guides on hormones, cycles, mental health, sleep, lifestyle and treatment options.
ReadTalk to Your GP
What to track beforehand, the precise words that change a consultation, and what to ask for.
ReadThis page is general health information, not personal medical advice. It is written to help you have a better conversation with a qualified clinician — not to replace one.